Table 1 Patient characteristics.
Healthy controls (n = 22) | dcSSc patients (n = 31) | lcSSc patients (n = 44) | |
|---|---|---|---|
Age, median (IQR) years | 46.5 (41.25–57.25) | 65 (51–71) | 55 (49–68) |
Sex, (female/male) | 17/5 | 28/3 | 42/2 |
Disease duration, median (IQR) years | 1.5 (0.6–2.5) | 2.0 (0.5–7.0) | |
Clinical features | |||
mRSS, median (IQR) | 16 (13.5–19) | 4 (2–6) | |
Raynaud's phenomenon | 21 (67.7) | 39 (88.6) | |
Nail fold bleeding | 21 (67.7) | 30 (68.2) | |
Pitting scar | 5 (16.1) | 10 (22.7) | |
Telangiectasia | 7 (22.6) | 5 (11.4) | |
Digital ulcers | 4 (12.9) | 8 (18.2) | |
Interstitial lung disease | 17 (54.8) | 13 (29.5) | |
Esophageal dysfunction | 30 (96.8) | 34 (77.3) | |
Pulmonary hypertension | 0 (0.0) | 1 (2.3) | |
Scleroderma renal crisis | 1 (3.2) | 0 (0.0) | |
Laboratory findings | |||
Anti-topoisomerase I | 10 (32.3) | 14 (31.8) | |
Anti-centromere | 1 (3.2) | 21 (47.7) | |
Anti-RNA polymerase III | 12 (38.7) | 3 (6.8) | |
